Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
about
An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trialA cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal featuresBimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical settingTolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost.Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients.A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionEvaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study.Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications.Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.
P2860
Q33706842-8E123D47-CE72-48D0-8C3C-5D3CC7A81C0EQ34708308-E51D2B1E-1ACF-4E67-9885-7E3F9FD2BE9CQ34901153-BE09F510-E9F2-4D24-8D0A-6D579ACC48F4Q36134942-978CC449-3647-4C7C-B82C-4C770F776933Q36487013-998CFD07-C56E-4108-9AE8-40821B9BAA5CQ36709208-0845230F-DDE9-4F41-91B4-39E181459C7CQ38598695-A3351E69-224B-402D-880E-51ADA2A19D12Q39831161-ADF03008-EB6D-4A26-8E9A-CECA6AE09974Q41200583-C619D669-8CAB-4FFB-8DD8-266D925E32CAQ42280470-B62FF292-8440-4297-A85B-9ED593492E22Q52995234-5C840932-4883-4E24-B3AB-9284663388D4
P2860
Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@ast
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@en
type
label
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@ast
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@en
prefLabel
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@ast
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@en
P2093
P2860
P356
P1476
Multicenter, prospective, open ...... aucoma or ocular hypertension.
@en
P2093
Birgit Mäder
Christoph Spraul
Dietmar Schnober
Gerrit von Kistowski
Hazel Cooper
Michael Froböse
Osman Ramez
Peter Eschstruth
Stefan Pfennigsdorf
Thomas Laube
P2860
P304
P356
10.2147/OPTH.S31330
P407
P577
2012-05-11T00:00:00Z